What Is Keratosis Pilaris?
Keratosis Pilaris (KP) is a benign but often cosmetically distressing skin condition characterized by rough, follicular papules, most commonly found on the upper arms, thighs, cheeks, and buttocks. The disorder stems from abnormal keratinization of hair follicles, resulting in the formation of small plugs that block follicular openings.
While not medically dangerous, KP can significantly affect quality of life, particularly in adolescents and young adults. Topical therapy remains the mainstay of treatment, and compounded options like those available on eNavvi can provide tailored, multi-mechanism therapy to maximize clinical response.
Pathophysiology: What’s Really Going On?
• Follicular hyperkeratinization: Overproduction of keratin traps hair shafts and leads to comedone-like plugs.
• Barrier dysfunction: KP often coexists with xerosis and atopic skin conditions.
• Inflammation: Chronic plugging can trigger perifollicular inflammation and erythema.
• Secondary pigment changes or scarring may occur in darker skin tones or with repeated trauma.
Who Gets Keratosis Pilaris?
• Children and Adolescents: Most common age of onset; may improve with age
• Atopic Individuals: Strong correlation with eczema, asthma, or allergic rhinitis
• Patients with Dry Skin: Worse in cold, dry climates
• Genetic Predisposition: Often autosomal dominant in inheritance
Clinical Features
• Rough “chicken skin” texture
• Sandpaper-like papules on extensor surfaces
• Red or brown hyperpigmentation (especially in Fitzpatrick III–VI)
• May be asymptomatic or pruritic
Treatment: Why Compounding?
Standard treatments include keratolytics (lactic acid, salicylic acid), retinoids, and emollients, but many over-the-counter options are underpowered, especially for inflammatory or resistant KP.
Compounded topicals provide:
• Higher concentration actives than OTC
• Combination therapies in a single application
• Formulations designed for patient tolerability
• Cost-effective options, with fast nationwide delivery through eNavvi
eNavvi’s Compounded Formula for Keratosis Pilaris
Diclofenac Sodium / Tacrolimus / Tretinoin / Ammonium Lactate
2% / 0.05% / 0.025% / 12%
Cream – 30 GMS – $45.00 / 30 Days – 2-Day Shipping Nationwide
When to Use This Formula
• Inflammatory KP with erythema and chronicity
• Refractory KP unresponsive to OTC urea/lactic acid
• Sensitive or atopic skin (tacrolimus offers a steroid-sparing option)
• Hyperkeratotic and pigmented lesions needing keratolytic + retinoid synergy
Mechanism Breakdown:
• Ammonium Lactate: Lactic acid derivative with keratolytic action. Softens keratin plugs and smooths skin texture.
• Tretinoin: Retinoid that increases cell turnover. Helps prevent follicular plugging.
• Diclofenac Sodium: NSAID and COX-inhibitor. Reduces perifollicular inflammation.
• Tacrolimus: Calcineurin inhibitor. Modulates immune response in inflammatory KP, especially useful for atopic skin.
Side Effects & Monitoring
• Tretinoin: Can cause irritation and peeling. Recommend starting every other night; combine with moisturizer and use sunscreen.
• Ammonium Lactate: May cause burning on broken skin. Avoid use on abraded or sensitive areas.
• Tacrolimus: May cause transient burning or stinging. Educate patients that this usually resolves with continued use.
• Diclofenac: May cause photosensitivity and mild dryness. Counsel on daily sun protection.
Clinical Tips
• Start low, go slow: Use every other night, increasing to nightly as tolerated.
• Combine with emollients: Apply a bland moisturizer in the morning.
• Expect improvement in 4–6 weeks: Complete clearance may take 8–12 weeks.
• Maintenance: Consider reducing frequency or switching to lactic acid monotherapy once improved.
Why eNavvi?
• Formulations Built for Function: High-potency actives with excellent base tolerability
• Affordable Pricing: $45 for a 30-day supply
• Rapid Fulfillment: 2-day delivery, all 50 states
• Provider-Ready Templates: Save time with pre-set prescriptions
• Clinical Flexibility: Adjust concentrations based on patient need
Conclusion
Keratosis pilaris can be more than a cosmetic nuisance—it often coexists with underlying inflammation, barrier dysfunction, and emotional distress. eNavvi’s compounded formula combining keratolytics, anti-inflammatories, and retinoids offers physicians a comprehensive and effective option, especially in treatment-resistant or atopic cases.
Tailored, potent, and accessible: compounded therapy represents the future of KP care.